Literature DB >> 26097546

Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease.

Jing-Wei Mao1, Hai-Ying Tang2, Ting Zhao3, Xiao-Yan Tan3, Jian Bi3, Bing-Yuan Wang1, Ying-De Wang3.   

Abstract

Intestinal mucosal barrier dysfunction is closely related to liver diseases, which implies impaired gut-liver axis may play a role in the pathogenesis of NAFLD. In our study, rats were divided into three groups: normal chow diet (NCD) group, high-fat diet (HFD) group and TNBS-induced colitis with high-fat diet (C-HFD) group. Liver tissues were obtained for histological observation and TNF-α, IL-6 mRNA determination and blood samples were collected for liver enzymes and LPS analysis. Ultrastructural changes of jejuna epithelium, SIBO and amounts of CD103(+)MHCII(+)DCs and CD4(+)CD25(+)FoxP3(+)T-regs in terms of percentage in mesenteric lymph nodes (MLN) were observed by electron microscope, bacterial cultivation and flow cytometry, respectively. The results demonstrated the pathological characteristics accorded with nonalcoholic simple fatty liver (NAFL) and NASH in HFD group by week 8 and 12, respectively. Besides, the degree of hepatic steatosis and steatohepatitis was more severe in C-HFD group compared with HFD-group at the same time point. NAFLD activity score (NAS), liver enzymes, concentration of LPS and mRNA expressions of TNF-α, IL-6 were higher significantly in C-HFD group compared with HFD and NCD group at week 4, 8 and 12, respectively. In HFD group, epithelium microvilli atrophy, disruptive tight junctions and SIBO were present, and these changes were more severe in NASH compared with NAFL. The percentage of CD103+MHCII+DCs and CD4+CD25+FoxP3+T-regs decreased significantly in NAFL and NASH compared with NCD group. Our conclusion was that gut-liver axis was impaired in NAFLD, which played crucial role in the pathogenesis of NAFLD.

Entities:  

Keywords:  IL-6; Nonalcoholic fatty liver disease; TNF-α; dendritic cell; intestinal mucosal barrier; regulatory T cell

Mesh:

Substances:

Year:  2015        PMID: 26097546      PMCID: PMC4466933     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

Review 1.  Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment.

Authors:  Sandra Milić; Davor Stimac
Journal:  Dig Dis       Date:  2012-06-20       Impact factor: 2.404

2.  Effect of Etiasa on the expression of matrix metalloproteinase-2 and tumor necrosis factor-α in a rat model of ulcerative colitis.

Authors:  Jing-Wei Mao; Hai-Ying Tang; Xiao-Yan Tan; Ying-De Wang
Journal:  Mol Med Rep       Date:  2012-08-07       Impact factor: 2.952

Review 3.  Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease.

Authors:  Hye-Jin Yoon; Bong Soo Cha
Journal:  World J Hepatol       Date:  2014-11-27

4.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

5.  Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats.

Authors:  Jing-Wei Mao; Xiao-Mei He; Hai-Ying Tang; Ying-De Wang
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

6.  Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.

Authors:  Luca Miele; Venanzio Valenza; Giuseppe La Torre; Massimo Montalto; Giovanni Cammarota; Riccardo Ricci; Roberta Mascianà; Alessandra Forgione; Maria L Gabrieli; Germano Perotti; Fabio M Vecchio; Gianlodovico Rapaccini; Giovanni Gasbarrini; Chris P Day; Antonio Grieco
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

7.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

8.  Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis.

Authors:  C Rinaldi A Lesmana; Irsan Hasan; Unggul Budihusodo; Rino A Gani; Ening Krisnuhoni; Nurul Akbar; Laurentius A Lesmana
Journal:  J Dig Dis       Date:  2009-08       Impact factor: 2.325

9.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

Review 10.  Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease.

Authors:  Un Ju Jung; Myung-Sook Choi
Journal:  Int J Mol Sci       Date:  2014-04-11       Impact factor: 5.923

View more
  21 in total

Review 1.  The role of the gut microbiota in NAFLD.

Authors:  Christopher Leung; Leni Rivera; John B Furness; Peter W Angus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

2.  Enteric dysbiosis is associated with sepsis in patients.

Authors:  Zhanguo Liu; Na Li; Heng Fang; Xiaojiao Chen; Yuexun Guo; Shenhai Gong; Mengwei Niu; Hongwei Zhou; Yong Jiang; Ping Chang; Peng Chen
Journal:  FASEB J       Date:  2019-08-28       Impact factor: 5.191

3.  Gut microbiota, fatty liver disease, and hepatocellular carcinoma.

Authors:  Huikuan Chu; Brandon Williams; Bernd Schnabl
Journal:  Liver Res       Date:  2018-02-21

Review 4.  Amelioratory Effect of Resistant Starch on Non-alcoholic Fatty Liver Disease via the Gut-Liver Axis.

Authors:  Weifeng Zhu; Ying Zhou; Rong Tsao; Huanhuan Dong; Hua Zhang
Journal:  Front Nutr       Date:  2022-05-17

5.  Marine Chitooligosaccharide Alters Intestinal Flora Structure and Regulates Hepatic Inflammatory Response to Influence Nonalcoholic Fatty Liver Disease.

Authors:  Jiayao Feng; Yongjian Liu; Jiajia Chen; Yan Bai; Jincan He; Hua Cao; Qishi Che; Jiao Guo; Zhengquan Su
Journal:  Mar Drugs       Date:  2022-06-07       Impact factor: 6.085

Review 6.  Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.

Authors:  Judith Aron-Wisnewsky; Chloé Vigliotti; Julia Witjes; Phuong Le; Adriaan G Holleboom; Joanne Verheij; Max Nieuwdorp; Karine Clément
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-03-09       Impact factor: 46.802

7.  Hyperreactivity of Blood Leukocytes in Patients with NAFLD to Ex Vivo Lipopolysaccharide Treatment Is Modulated by Metformin and Phosphatidylcholine but Not by Alpha Ketoglutarate.

Authors:  Agnieszka Zwolak; Agnieszka Szuster-Ciesielska; Jadwiga Daniluk; Olga Słabczyńska; Martyna Kandefer-Szerszeń
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

Review 8.  Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease.

Authors:  Marco Poeta; Luca Pierri; Pietro Vajro
Journal:  Children (Basel)       Date:  2017-08-02

9.  The Potential Effect of Chinese Herbal Formula Hongqijiangzhi Fang in Improving NAFLD: Focusing on NLRP3 Inflammasome and Gut Microbiota.

Authors:  Shu Liang; Yupei Zhang; Yuanjun Deng; Yifang He; Yinji Liang; Zien Liang; Yanning Chen; Kairui Tang; Runsen Chen; Qinhe Yang
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-21       Impact factor: 2.629

Review 10.  Connecting the Dots Between Inflammatory Bowel Disease and Metabolic Syndrome: A Focus on Gut-Derived Metabolites.

Authors:  Andrea Verdugo-Meza; Jiayu Ye; Hansika Dadlani; Sanjoy Ghosh; Deanna L Gibson
Journal:  Nutrients       Date:  2020-05-15       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.